Note 1  Organization and Business ProPhase Labs, Inc. (we, us or the Company) was initially organized in Nevada in July 1989. Effective June 18, 2015, we changed our state of incorporation from the State of Nevada to the State of Delaware. We are a manufacturer, marketer and distributor of a diversified range of health care and cold remedy products that are offered to the general public. We are also engaged in the research and development of potential over-the-counter (OTC) drug and natural base health products including supplements, personal care and cosmeceutical products. Discontinued Operations Prior to March 29, 2017, our flagship OTC drug brand was Cold-EEZE  and our principal product was Cold-EEZE  cold remedy zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold. In addition to Cold-EEZE  cold remedy lozenges, we also marketed and distributed non-lozenge forms of our proprietary zinc gluconate formulation, (i) Cold-EEZE  cold remedy QuickMelts  , (ii) Cold-EEZE  Gummies and (iii) Cold-EEZE  cold remedy Oral Spray. Each of the Cold-EEZE  QuickMelts  and Gummies products are based on a proprietary zinc gluconate formulation in combination with certain (i) immune system support, (ii) energy, (iii) sleep and relaxation, and/or (iv) cold and flu symptom relieving active ingredients. On January 6, 2017, we signed an asset purchase agreement (as amended, the Asset Purchase Agreement), by and among the Company, Meda Consumer Healthcare Inc. (MCH) and Mylan Inc. (together with MCH, Mylan), for the sale of assets by us to Mylan (see Note 3). The sale of assets (i) was subject to stockholder approval and other customary closing conditions and (ii) consisted principally of the sale of our intellectual property rights and other assets relating to our Cold-EEZE  brand and product line (collectively, referred to herein as the Cold-EEZE  Business) to Mylan, including all current and pipeline over-the-counter allergy, cold, flu, m